 "Natco Pharma receives FDA inspection report on Kothur formulations facility")
Natco Pharma on Thursday announced it had received the Establishment Inspection Report (EIR) from the United States (US) Food and Drug Administration (FDA) for the inspection conducted at its drug formulations facility at Kuthur Unit, Telangana.
EIR is given when the unit meets the expectations of the US drug regulator on current good manufacturing practice (CGMP) regulations and other aspects. According to the company, the inspection was conducted from January 16 to January 24. This formulations facility predominantly caters to regulated international markets, including the US.
The Hyderabad-based generics company has five formulations facilities in India — two in Dehradun, one in Kothur (Telangana), one near Nagarjuna Sagar (Telangana) and one in Guwahati (Assam). It also has two API units, one in Telangana and the other one in Chennai, Tamil Nadu.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app